Abstract：Objective To explore the influence of pulmonary rehabilitation combining with budesonide/formoterol and tiotropium on pulmonary function and quality of life （QOL）in patients with chronic obstructive pulmonary diseases （COPD）.Methods From July 2013 to December 2015，95 patients with severe and extremely severe COPD at a stable stage in our hospital were selected and randormly divided into group A，group B and group C.In group A（n=31），inhalation of budesonide/formoterol was used for treatment；In group B （n=32），inhalation of budesonide/formoterol combining with tiotropium was adopted；In group C （n=32），on the basis of the group B，pulmonary rehabilitation was added.Pulmonary function，Modified Version of the British Medical Research Council Respiratory Questionnaire （mMRC），and 6-minute walking distance （6-MWD）were detected before treatment and 3 months after treatment.The forced expiratory volume in one second （FEV1），percentage of FEV1on predicted value，and FEV1/FVC were calculated.The changes of monitoring indexes before and after treatment among three groups were compared.Results After 3-month treatment，FEV1，percentage of FEV1on predicted value，FFEV1/FVC，mMRC，and 6-MWD were all improved among three groups compared with those before treatment，which were displayed statistical differences （P＜0.05）；These indexes in group C were much better than those in group A and group B，which were displayed statistical difference among inter-group comparisons（P＜0.05）.Conclusion For patients with severe and extremely severe COPD at a stable stage，pulmonary rehabilitation combining with budesonide/formoterol and tiotropium has a better synergistic effect in comparison with that by budesonide/formoterol or budesonide/formoterol and tiotropium，which greatly improves patient′s pulmonary function and QOL and is worthy of promotion.
刘汉坤;周明;吴志强. 肺康复联合布地奈德/福莫特罗和噻托溴铵治疗重度和极重度稳定期COPD的效果[J]. 中国当代医药, 2016, 23(15): 23-25.
LIU Han-kun;ZHOU Ming;WU Zhi-qiang. Effect of Pulmonary rehabilitation combining with budesonide/formoterol and tiotroPium on treating stable-stage severe and extremely severe COPD. 中国当代医药, 2016, 23(15): 23-25.
Beauchamp MK，Francella S，Romano JM，et al.A novel approach to long-term respiratory care：results of a community-based post-rehabilitation maintenance program in COPD［J］.Respir Med，2013，107（8）：1210-1216.
［8］
Maris NA，de Vos AF，Dessing MC，et al.Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers［J］.Am J Respir Crit Care Med，2005，172（7）：878-884.
［9］
Singh D，Blooks J，Hagan G，et al.Superiority of"triple" therapy with salmeterol/fluticasome propionate and tiotropium bromide versus individual components in moderate to severe COPD［J］.Thorax，2008，63（7）：592-598.
［11］
Tashkin DP，Celli B，Senn S，et al.A 4-year trail of tiotropium in chronic obstructive pulmonary disease［J］.N Engl J Med，2008，359（15）：1543-1554.
［12］
Decramer M，Celli B，Tashkin DP，et al.Clinical trail design considerations in assessing long-term functional impacts of tiotropium in COPD：the UPLIFT trial［J］.COPD，2004，1（2）：303-312.
［15］
Egan C，Deering BM，Blake C，et al.Short term and long term effects of pulmonary rehabilitation on physical activity in COPD［J］.Respir Med，2012，106（12）：1671-1679.
［16］
Vestbo J，Hurd SS，Agusti AG，et al.Global strategy for the diagnosis，management，and prevention of chronic obstructive pulmonary disease：GOLD executive summary［J］.Am J Respir Crit Care Med，2013，187（4）：347-365.
京公网安备 11010502046607号